Dernières nouvelles pour NovoCure (NASDAQ:NVCR) Stock

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

WIIM

UXIN

Uxin shares are trading higher after the company announced a strategic partnership with Wuhan City Economic & Technological Development Zone.

<a href="https://www.wsj.com/business/media/nbcuniversal-to-stream-local-sports-on-peacock-in-bid-for-cord-cutters-68e1d941?mod=latest_headlines" title="https://www.wsj.com/business/media/nbcuniversal-to-stream-local-sports-on-peacock-in-bid-for-cord-cutters-68e1d941?mod=latest_headlines">https://www.wsj.com/business/media/nbcuniversal-to-stream-local-sports-on-peacock-in-bid-for-cord-cutters-68e1d941?mod=latest_headlines</a>

News

CMCSA

NBCUniversal To Add Regional Sports Channels To Peacock Streaming Service Starting In Early 2025, Including Boston, Philadelphia, And Northern California Markets

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported fourth-quarter fiscal year 2024 sales of $37.55 billion on Tuesday. 
That&#8217;s up 6% year over year (+6.1% on constant currency). The numbers beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $35.76 billion</a>, reflecting sales growth across all segments.
Walgreens Boots Alliance announced a footprint optimization program targeting approximately 1,200 closures over the next three years. This includes approximately 500 closures in fiscal 2025, which will be immediately accretive to adjusted <a href="https://www.benzinga.com/news/earnings/24/10/41333092/walgreens-boots-alliance-outlines-three-cost-saving-strategy-as-q4-earnings-beat-street-estimates" target="_blank" rel="noreferrer noopener">EPS and free cash flow</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41279374/cvs-health-positioned-for-medicare-margin-expansion-and-market-share-gains-says-bar" rel="noreferrer noopener">CVS Health Positioned For Medicare Margin Expansion And Market Share Gains, Says Barclays Analyst</a>.
The company said it exceeded fiscal 2024 targets for&nbsp;$1 billion&nbsp;in cost savings,&nbsp;a $600 million&nbsp;reduction in capital expenditures, and&nbsp;$500 million&nbsp;in working capital initiatives.
Truist Securities noted that Walgreens Boots Alliance finished the fiscal year 2024 on a strong note, meeting management&#8217;s expectations and exceeding projections for both revenue and earnings.
The fiscal 2025 guidance reflects optimism, aligning with the higher end of Truist Securities&#8217; and consensus forecasts.
Both international and U.S. healthcare segments delivered solid performances despite ongoing challenges in consumer spending and pharmacy reimbursement pressures. However, the outlook on reimbursement was positive. Fourth-quarter cash flow surpassed expectations and remains a critical focus, while capital expenditures and working capital improvements are encouraging.
Truist <a target="_blank" href="https://www.benzinga.com/quote/WBA/analyst-ratings" rel="noreferrer noopener">maintains the Hold rating</a>, with a price target of $10.
RBC Capital notes that Walgreens Boots Alliance has outlined its planned store closures through 2027, offering greater clarity and reducing the uncertainty around the higher end of potential closures.
The analyst also highlights that Walgreens is investing in locations it anticipates will absorb prescriptions and foot traffic from the closing stores. 
Having already shuttered a few hundred locations in fiscal year 2024, the company has recent experience managing patient transitions and prescription volumes.
Evercore ISI maintains Walgreens Boots Alliance with an In-Line rating and raises the price target from $7.5 to $10.
Price Action: WBA stock is up 4.32% at $10.87 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41362705/sofi-boosts-payment-services-with-galileos-cloud-based-cyberbank-core" target="_blank" rel="noreferrer noopener">SoFi Boosts Payment Services with Galileo&#8217;s Cloud-Based Cyberbank Core</a>.</li>
</ul>
Image: Shutterstock

Analyst Color

Health Care

Analyst Ratings

Movers

Trading Ideas

General

Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 9.16%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Underweight rating and cut the price target from $9 to $7 on Oct. 11. This analyst has an accuracy rate of 75%.</li>
<li>Truist Securities analyst David Macdonald maintained a Hold rating and cut the price target from $13 to $10 on Oct. 7. This analyst has an accuracy rate of 74%</li>
<li>Recent News: On Tuesday, Walgreens reported fourth-quarter fiscal year 2024 sales of $37.55 billion, up 6% year over year (+6.1% on constant currency), beating the consensus of $35.76 billion, reflecting sales growth across all segments.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">latest WBA news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="913" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127.png" alt="" class="wp-image-599050" style="width:538px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143111/image-127-768x707.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</h3>
<ul>
<li>Dividend Yield: 4.73%</li>
<li>B of A Securities analyst Bryan Spillane maintained a Neutral rating and cut the price target from $34 to $33 on Oct. 3. This analyst has an accuracy rate of 65%.</li>
<li>Evercore ISI Group analyst David Palmer maintained a Neutral rating and lowered the price target from $32 to $31 on July 12. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On Oct. 2, ConAgra Brands reported worse-than-expected first-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted t<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">o latest CAG news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128.png" alt="" class="wp-image-599053" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143147/image-128-768x710.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</h3>
<ul>
<li>Dividend Yield: 4.47%</li>
<li>Goldman Sachs analyst Bonnie Herzog maintained a Buy rating and raised the price target from $126 to $140 on Sept. 26. This analyst has an accuracy rate of 69%.</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and boosted the price target from $130 to $145 on Sept. 9. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: Philip Morris will host a live audio webcast on Tuesday, Oct. 22 to discuss its third-quarter results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">trend in PM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129.png" alt="" class="wp-image-599056" style="width:696px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16143219/image-129-768x716.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Dividends

Price Target

Markets

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

Zimmer Biomet Holdings, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zbh#NYSE">ZBH</a>) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.
In the last reported quarter, the company&#39;s earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average surprise being 2.84%.
<h2>ZBH&#39;s Q3 Estimates</h2>
The Zacks Consensus Estimate for revenues is pegged at $1.81 billion, suggesting a 3.3% rise from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $1.75 per share, indicating a 6.1% improvement from the year-ago reported numbers.
<h2>Estimate Revision Trend Ahead of ZBH&#39;s Q3 Earnings</h2>
The Zacks Consensus Estimate for earnings has moved south 1.1%&nbsp; to $1.75 per share in the past 30 days.
Let&#39;s briefly look at how things might have shaped up for this MedTech major in the to-be-reported quarter.
<h2>Factors at Play</h2>
Zimmer Biomet is likely to have experienced strong growth in the&nbsp;third quarter on the back of strong performance from its business segments.
The Hip business is expected to have witnessed growth due to the company&#39;s comprehensive suite of solutions in navigation in direct anterior stems and surgical impactors.
While this business lagged&nbsp;the broader market during the second quarter due to key portfolio gaps, the company has made significant progress with new product introductions. During the same quarter, Zimmer Biomet launched the&nbsp;surgical impactor HAMMR, whose adoption has been great so far. Additionally, during the&nbsp;third-quarter, the company entered into a definitive agreement to acquire OrthoGrid Systems, Inc. The acquisition includes OrthoGrid&#39;s AI-powered, fluoroscopy-based surgical assistance platform&nbsp;Hip AI, as well as two additional FDA-cleared orthopedic applications and over 40 patents.
Outside the United States, ZBH expects to launch a second generation of hip posterior robotics. Banking on these developments, the company is expected to report a strong revenue increase within this category in the third quarter.
Within the Knees business, the company faced some challenges from a supply standpoint. These are high ASP cases.
<h2>Zimmer Biomet Holdings, Inc. Price and EPS Surprise</h2>
<div class="chart_embed"><img alt="Zimmer Biomet Holdings, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1729087518.png" style="height:263px; width:544px" title="" />
Zimmer Biomet Holdings, Inc. price-eps-surprise | Zimmer Biomet Holdings, Inc. Quote
</div>
Although this business in the United States was softer than expected, the company delivered knee growth of 5% year over year in the second quarter. We expect this growth trend to have continued in the third quarter as well.&nbsp;
The company expects to launch two different ROSA for knees in the coming three to eight quarters. In addition to ROSA, Zimmer Biomet has a partnership with THINK Surgical for TMINI &mdash; a&nbsp;miniature handheld robotic system for total knee arthroplasty. TMINI was supposed to be released in the second half of 2024. These developments might have had a positive impact on the company&#39;s third-quarter top-line performance.
In the second quarter, the S.E.T business grew mid-single digits, led by key focus areas of CMFT, upper extremities and sports growing on average high-single digits. The second quarter of 2024 was the third quarter in a row to experience such growth. Every single business within S.E.T. grew for the first time in the&nbsp;second quarter. We expect this trend to have continued in the third quarter as well.
<h2>What Our Model Suggests for ZBH</h2>
Per our proven model, a stock with a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Zimmer Biomet has an Earnings ESP of -1.65%%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Strong).
<h2>Stocks Worth a Look</h2>
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Atea Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avir#NASDAQ">AVIR</a>) has an Earnings ESP of +13.13% and a Zacks Rank #1 at present.
The company is expected to release third-quarter 2024 results on Nov. 13. AVIR&#39;s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 5.23%.
RadNet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>)&nbsp;has an Earnings ESP of +20.00% and a Zacks Rank #2 at present. The company is expected to release third-quarter 2024 results on Nov. 13.
RDNT&#39;s earnings surpassed estimates in three of the trailing four quarters and broke even once, the average surprise being 98.23%. The Zacks Consensus Estimate for RadNet&#39;s third-quarter EPS is expected to increase 21.4% from the year-ago quarter&#39;s reported numbers.
TransMedics Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) has an Earnings ESP of +26.63% and a Zacks Rank #3 at present. The company is likely to release third-quarter 2024 results on Nov. 4. The Zacks Consensus Estimate for the company&#39;s third-quarter EPS implies a surge of 333.3% from the year-ago quarter&#39;s reported figure.
<a href="https://www.zacks.com/stock/news/2351618/zbh-gears-up-for-q3-earnings-what-lies-ahead-for-the-stock?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2351618">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

Penny Stocks

Small Cap

AVIR

RDNT

TMDX

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

It's no secret that cannabis companies are facing some formidable challenges when it comes to raising capital, thanks to marijuana&#8217;s onerous classification as a <a href="https://www.benzinga.com/markets/cannabis/24/02/36916329/is-marijuana-a-controlled-substance-wait-what-is-a-controlled-substance" target="_blank" rel="noreferrer noopener">Schedule I controlled substance</a> under federal law. But now with potential changes on the horizon, such as cannabis rescheduling and banking reform, more companies just might improve their financial positions and attract new investments.
Even now, in anticipation of potential regulatory changes, there's been an increase in capital raises. Frank Colombo, managing director of data analytics and investment banking at Viridian Capital Advisors, provided an overview of capital raising trends the <a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">Benzinga Cannabis Capital Conference</a>. He told the crowd gathered in Chicago there&#8217;s been an increase of 14.8% in capital raises in 2024, driven mostly by Canadian equities and U.S. debt.
Colombo said U.S. debt accounts for over 50% of capital raises, indicating a reliance on debt financing rather than equity in the market. Retail and cultivation sectors are responsible for half of all capital raises. However, out of 12 different sectors, &#8220;investments in M&amp;A" were &#8220;really up,&#8221; <a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">he explained.</a>
<h3 class="wp-block-heading">But Still&#8230;Cannabis Debt Looms</h3>
Green Market Report's Debra Borchardt took a closer look at what she called it "a tsunami of debt headed straight for the cannabis industry," or approximately $1.83 billion of the debt that's due by 2026 that many public marijuana operators opted for earlier as they lacked much-needed capital.
According to regulatory filings for the publicly traded businesses in the industry large cannabis operators Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>), Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) and Verano Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTCQX">VRNOF</a>) are about to face debt maturities in 2026, <a href="https://www.greenmarketreport.com/tsunami-of-debt-heading-toward-the-biggest-cannabis-companies/">explained</a> Borchardt who was also a guest at Benzinga&#8217;s conference in Chicago.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
While these companies have yet to navigate considerable debt challenges while focusing on their growth and operations, other big players in the space have successfully managed their respective debts, at least for now.
Borchardt highlighted Ascend Wellness Holdings' (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>) and Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) "preemptive actions" to address their growing debt issues while mentioning TerrAscend Corp.&#8217;s (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSND#TSX">TSND</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>) FG Loan which will mature in 2028.
New York-headquartered Ascend closed its <a href="https://www.benzinga.com/markets/cannabis/24/07/39776292/ascend-wellness-to-issue-235m-of-senior-secured-notes-to-prepay-215m-under-term-loan">previously announced</a> private placement of $235 million of 12.75% senior secured notes due 2029 in July with plans to prepay $215 million of principal amounts <a href="https://www.benzinga.com/markets/cannabis/24/07/39839510/ascend-wellness-cannabis-co-closes-235m-private-placement-of-senior-secured-notes-refinances-exi">outstanding under its existing term loan.</a>
Meanwhile, the owner of RISE Dispensaries closed on a $150 million 5-year syndicated credit facility led by Valley National Bank, the principal subsidiary of Valley National Bancorp which will allow it to retire its $225 million <a href="https://www.benzinga.com/markets/cannabis/24/09/40834346/cannabis-giant-green-thumb-secures-150m-credit-facility-strengthens-our-already-clean-balance-sh">senior secured debt due April 30, 2025.</a>
Jason Wild, executive chairman of TerrAscend said the <a href="https://www.benzinga.com/markets/cannabis/24/08/40133450/terrascend-cannabis-wraps-up-140m-debt-financing-no-other-material-debt-maturing-until-2027-says">recent completion</a> of the second and final draw of $26 million as part of its $140 million senior secured term loan, <a href="https://www.benzinga.com/markets/cannabis/24/10/41130165/cannabis-company-terrascend-secures-second-and-final-26m-loan-reduces-debt-in-michigan">enabled the company to have</a> "no other material debt maturing until late 2027."
<h3 class="wp-block-heading">Financial Institutions Set To Earn Billions In Interest Revenue</h3>
A new report from Whitney Economics backed by CTrust and Green Check projects that the U.S. cannabis industry will need between $65.6 billion and $130.7 billion in sustainable growth capital to support new cannabis businesses and help refinance existing ones over the next decade.
On the flip side, the market will generate roughly $1 billion to $2.4 billion in potential interest revenue for financial institutions willing to lend to cannabis businesses, over the same period, <a href="https://www.benzinga.com/markets/cannabis/24/10/41335229/cannabis-industrys-130b-growth-potential-top-states-for-investment-as-financial-institutions-set">according to the report.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241003/exclusive-cannabis-rescheduling-is-not-cure-all-for-industry-problems-experts-explain-how-tax-ta">Cannabis Industry&#8217;s $130B Growth Potential: Top States For Investment As Financial Institutions Set To Earn Billions In Interest Revenue, New Report Reveals</a></li>
</ul>

Cannabis

Financing

AAWH

CRLBF

CSE:GTII

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

GTII

TCNNF

TRUL

TSNDF

TSX:TSND

VRNOF

Cannabis Debt Looms For These Weed Giants: Here's How Some Tackled Their Financial Challenges

Investors with a lot of money to spend have taken a bearish stance on Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with LRN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Stride.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 44%, bearish.
Out of all of the options we uncovered, 8 are puts, for a total amount of $322,830, and there was 1 call, for a total amount of $101,600.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $80.0 for Stride, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Stride options trades today is 652.86 with a total volume of 2,003.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Stride's big money trades within a strike price range of $55.0 to $80.0 over the last 30 days.
<h3>Stride Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104351_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.0</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$70.00</td>
<td>$101.6K</td>
<td style="text-align: right;">77</td>
<td style="text-align: right;">273</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.4</td>
<td>$2.75</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$80.0K</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$12.4</td>
<td>$11.4</td>
<td>$11.76</td>
<td>$80.00</td>
<td>$47.0K</td>
<td style="text-align: right;">491</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$5.2</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$65.00</td>
<td>$42.8K</td>
<td style="text-align: right;">712</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$6.4</td>
<td>$3.7</td>
<td>$4.5</td>
<td>$75.00</td>
<td>$33.3K</td>
<td style="text-align: right;">542</td>
<td style="text-align: right;">84</td>
</tr>
</tbody>
</table>

<h3>About Stride</h3>
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional, and Private Pay Schools and Other.
Following our analysis of the options activities associated with Stride, we pivot to a closer look at the company's own performance.
<h3>Stride's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,840,323, the LRN's price is down by -2.68%, now at $68.7. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Stride</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $90.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barrington Research keeps a Outperform rating on Stride with a target price of $90. 
&#x2A; Maintaining their stance, an analyst from Barrington Research continues to hold a Outperform rating for Stride, targeting a price of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Stride with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on Stride: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NET usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Cloudflare. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $78,475, and 8 are calls, amounting to $451,000.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $110.0 for Cloudflare over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cloudflare stands at 570.12, with a total volume reaching 1,625.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cloudflare, situated within the strike price corridor from $70.0 to $110.0, throughout the last 30 days.
<h3>Cloudflare 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104346_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$23.65</td>
<td>$22.95</td>
<td>$23.23</td>
<td>$70.00</td>
<td>$76.6K</td>
<td>27</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.95</td>
<td>$21.2</td>
<td>$21.68</td>
<td>$70.00</td>
<td>$71.5K</td>
<td>60</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.68</td>
<td>$2.62</td>
<td>$2.68</td>
<td>$110.00</td>
<td>$67.2K</td>
<td>1.6K</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$3.15</td>
<td>$2.64</td>
<td>$3.15</td>
<td>$90.00</td>
<td>$62.0K</td>
<td>1.2K</td>
<td style="text-align: right;">543</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$94.00</td>
<td>$51.0K</td>
<td>206</td>
<td style="text-align: right;">119</td>
</tr>
</tbody>
</table>

<h3>About Cloudflare</h3>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
In light of the recent options history for Cloudflare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Cloudflare's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,376,225, the price of NET is down by -2.39%, reaching $91.56.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 22 days from now.</li>
</ul>
<h3>What The Experts Say On Cloudflare</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $65.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Exane BNP Paribas lowers its rating to Underperform with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cloudflare with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Cloudflare

High-rolling investors have positioned themselves bullish on Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ESTC often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Elastic. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $72,250, and 8 calls, totaling $493,658.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $85.0 for Elastic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Elastic's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Elastic's whale trades within a strike price range from $80.0 to $85.0 in the last 30 days. 
<h3>Elastic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104341_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.5</td>
<td>$9.7</td>
<td>$80.00</td>
<td>$184.2K</td>
<td>1.2K</td>
<td style="text-align: right;">330</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$9.7</td>
<td>$9.5</td>
<td>$9.6</td>
<td>$80.00</td>
<td>$98.8K</td>
<td>1.2K</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>ESTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$85.00</td>
<td>$72.2K</td>
<td>124</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$10.1</td>
<td>$80.00</td>
<td>$64.6K</td>
<td>1.2K</td>
<td style="text-align: right;">521</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$80.00</td>
<td>$33.9K</td>
<td>1.2K</td>
<td style="text-align: right;">365</td>
</tr>
</tbody>
</table>

<h3>About Elastic</h3>
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
After a thorough review of the options trading surrounding Elastic, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Elastic Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 314,355, the ESTC's price is up by 0.66%, now at $82.72. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Elastic with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ESTC

Market Whales and Their Recent Bets on ESTC Options

MoneyLion shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform rating and announced a $60 price target.

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and maintains $30 price target.

Reiteration

ASPN

HC Wainwright & Co. Reiterates Buy on Aspen Aerogels, Maintains $30 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639df5064ed0001400135/david-manthey">Baird analyst David Manthey</a> upgraded the rating for W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Neutral to Outperform and raised the price target from $975 to $1,230. Grainger shares closed at $1,085.57 on Tuesday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Begleiter upgraded Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Underperform to Neutral and boosted the price target from $151 to $159. Westlake shares closed at $141.80 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Atif Malik upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and increased the price target from $52 to $62. Cisco shares closed at $54.08 on Tuesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cleveland Research upgraded the rating for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) from Neutral to Buy. SAP shares closed at $229.52 on Tuesday. <a href="https://www.benzinga.com/quote/SAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and increased the price target from $13 to $22. WAVE Life Sciences shares closed at $8.56 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png" alt="" class="wp-image-599072" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Upgrades

CSCO

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Brookdale Senior Living shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $8 price target.

HC Wainwright &amp; Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) with a Buy and maintains $28 price target.

CGEM

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target

Jefferies analyst Trevor Williams maintains WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) with a Hold and raises the price target from $190 to $210.

Jefferies Maintains Hold on WEX, Raises Price Target to $210

HC Wainwright &amp; Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) with a Buy and maintains $7 price target.

OKYO

HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target

PC maker Lenovo Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNVGF#OTC">LNVGF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNVGY#OTC">LNVGY</a>) tapped Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance its artificial intelligence (AI) capabilities in markets outside China.
The U.S. semiconductor sanctions have barred China from accessing sophisticated AI chips from U.S. chip designers like Nvidia, citing national security threats. The embargo prompted Nvidia to develop the sanction-compliant <a target="_blank" href="https://www.benzinga.com/news/24/10/41317732/whats-going-on-with-nvidia-stock-on-monday" rel="noreferrer noopener">A800, H800, and H20 chips</a>.
At its annual Tech World conference in Seattle, Lenovo introduced AI Now, a personal AI assistant for PCs sold outside China, built on Meta&#8217;s open-source Llama 3.1 large language model, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3282586/lenovo-partners-meta-nvidia-ai-outside-china" rel="noreferrer noopener">reports</a>.
Lenovo&#8217;s AI assistant operates locally without an internet connection and can use natural language prompts to perform tasks like document management, text and image generation, and device configuration.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41358664/whats-going-on-with-intel-stock-wednesday" rel="noreferrer noopener">What&#8217;s Going On With Intel Stock Wednesday?</a>
In addition to AI Now, Lenovo announced a deepened partnership with Nvidia to launch enterprise-focused AI solutions.
The new AI server, the Lenovo ThinkSystem SC777 V4 Neptune, features Nvidia&#8217;s Blackwell graphics processing units (GPUs) and Lenovo&#8217;s advanced water-cooling technology.
Lenovo faces ongoing risks tied to geopolitical tensions, particularly concerning supply chains. The company is leveraging AI to mitigate these risks through its AI-powered Supply Chain Intelligence solution, which has already reduced manufacturing and logistics costs by 20%.
Lenovo also introduced a new AI-powered PC, the ThinkPad X1 2-in-1 Gen 10 Aura Edition, and concept prototypes like the Lenovo &#8220;AI Buddy,&#8221; which assists users with daily tasks.
Lenovo reported a 20% jump in its first-quarter topline, reaching a revenue of <a target="_blank" href="https://investor.lenovo.com//en/financial/results.php" rel="noreferrer noopener">$15.4 billion</a>.
Canalys projects shipments of 44 million AI PCs in 2024, and IDC expects AI PC shipments to reach around 50 million during the year, Forbes <a target="_blank" href="https://www.forbes.com/sites/bethkindig/2024/09/12/ai-pcs-have-arrived-shipments-rising-competition-heating-up/" rel="noreferrer noopener">reported</a>.
For context, Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) are vying for the <a target="_blank" href="https://www.benzinga.com/news/24/08/40347392/apple-intel-and-amd-lead-charge-in-ai-capable-pc-market-surge-report" rel="noreferrer noopener">AI PC market</a> as Nvidia rules the AI data center market.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41357485/intel-partners-with-amd-to-counter-arms-rising-dominance-in-computing" target="_blank" rel="noreferrer noopener">Intel Partners With AMD To Counter Arm&#8217;s Rising Dominance in Computing</a></li>
</ul>
Photo by Robert Way via Shutterstock

Government

Regulations

Tech

Media

INTC

LNVGF

LNVGY

NVDA

Lenovo's AI Push Grows with Meta, Nvidia Collaboration Outside China

Most investors inconsistently view quarterly earnings as a catalyst for stock prices upon the news release. They often find themselves trapped in the volatility of sudden moves and face the risk of large&mdash;or total, in the case of options&mdash;losses if the direction of the stock after the announcement goes the wrong way.
There is a way to somewhat accurately predict where a stock could go after earnings announcements or to see where broader markets are betting these stocks could go on the event. Keeping the saying &quot;it must be expensive for a reason&quot; in mind can be useful for investors in these scenarios, likewise for cheapness. Here are three stocks becoming &lsquo;expensive&#39; before they report earnings this month and why markets are willing to pay.
Aerospace and defense stock Lockheed Martin Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmt#NYSE">LMT</a>), wireless and communications provider T-Mobile US Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmus#NASDAQ">TMUS</a>), and even technology stock CoStar Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/csgp#NASDAQ">CSGP</a>) are some of the stocks reporting their subsequent quarrel earnings this month, and they all share the common factor of commanding valuation premiums compared to their peers. This is why markets might be willing to overpay for these stocks ahead of their announcements.
<h2>Lockheed Martin Positioned for Strong Quarter as Middle East Conflicts Drive Rising Arms Demand</h2>
As conflicts in the Middle East arise and escalate, the United States and its military allies will have to call upon domestic arms manufacturers like Lockheed Martin to help control and handle these situations accordingly, creating new demand for contracts in the company.
Investors can see this trend taking on momentum through a government contract database, spotting a new inflow of up to $599 million worth of government contracts going to Lockheed Martin to prepare responses against these conflicts, something markets are starting to bet on as the possibility of optimistic guidance and maybe even an earnings beat.
Knowing that a strong quarter is likely, markets are now willing to pay up to 21.5x the price-to-book (P/B) ratio, which is a significant premium over the rest of the aerospace sector&#39;s average valuation of 5.6x today. The optimism doesn&#39;t stop there for Lockheed Martin stock, though; others on Wall Street share the same bullish view.
Analysts at Citigroup decided to reiterate their &quot;Buy&quot; rating for the stock as recently as October 2024, this time seeing a price valuation of up to $700 a share. To prove these new views right, Lockheed Martin would need to rally by as much as 14.4% from where it trades today, not to mention a new 52-week high price for the company.
Lastly, investors can see signs of bearish capitulation in the face of all this bullish sentiment and evidence, as Lockheed Martin stock&#39;s short interest declined by as much as 18.8% over the past month alone, leaving room for new bulls to come in before the earnings are out.
<h2>T-Mobile Stock Gains New Premium as Subscription Business Strengthens</h2>
During times of higher inflation, such as today, and especially during economic uncertainty, businesses with subscription-based models tend to do well, considering their predictability and stability in cash flows and profits. Compared to peers like AT&amp;T Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>) and Verizon Communications Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>), T-Mobile stands apart in strategy.
Competitors fell behind in investing heavily in fiber communications, which not only eat up a lot of cash but also pose significant weather risk, some of the issues that T-Mobile&#39;s fixed wireless model does not have to endure. Fixed wireless is less capital-intensive and safer, and that superior quality keeps the company a leadership state compared to peers.
This is also why markets are willing to overpay for T-Mobile stock ahead of its earnings announcement. Compared to the rest of the communications industry&#39;s average P/B ratio of 1.4x today, T-Mobile stock commands a premium of 3.9x today. Knowing that the business&#39; investments are superior to peers and that is drawing more business, markets are rightfully bullish before earnings.
Analysts at Benchmark have recently boosted their price targets for T-Mobile stock as well, this time shooting for $250 a share, which calls for up to 16% upside from where T-Mobile stock trades today.
<h2>Double-Digit Upside Ahead for CoStar Group Stock</h2>
Combining the power of data and technology to the real estate sector is CoStar&#39;s value proposition for investors, one Wall Street is surely bullish on before the company&#39;s next earnings announcement. Starting with analysts, here&#39;s what they say about the company&#39;s future.
Those at Needham &amp; Co. see CoStar Group stock trading as high as $107 a share, calling for a net upside of 38.4% from today&#39;s stock price, not to mention a new 52-week high. Knowing that the industry is in dire need of data to aid in decision-making during shifting interest rates, markets bet that the stock is going to deliver a strong quarter.
Looking into valuations, CoStar Group stock trades at 145.9x price-to-earnings (P/E) ratio today, compared to the rest of the business services industry&#39;s average 43.0x average P/E today. Another premium to consider ahead of earnings is to be justified by potential financial outperformance.
To close the loop on this view, investors can note CoStar Group stock&#39;s falling short interest, which declined by 4.6% during the past month alone. This shows investors another sign of bullishness through bearish capitulation in the stock recently.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-stocks-investors-dont-want-to-miss-ahead-of-earnings/">3 Stocks Investors Don&#39;t Want to Miss Ahead of Earnings</a>&quot; first appeared on MarketBeat.

Guidance

Contracts

Economics

CSGP

TMUS

3 Stocks Investors Don't Want to Miss Ahead of Earnings

Jefferies analyst Trevor Williams maintains Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) with a Buy and raises the price target from $375 to $425.

CPAY

Jefferies Maintains Buy on Corpay, Raises Price Target to $425

Macquarie analyst Tim Nollen maintains Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) with a Outperform and raises the price target from $110 to $120.

Macquarie Maintains Outperform on Omnicom Group, Raises Price Target to $120

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains the...

NovoCure Leadership Transition Signals Stability and Earns Buy Rating

Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM

Novocure gets FDA approval for its lung cancer treatment

NovoCure ( ($NVCR) ) has shared an update. The FDA has approved Novocure's Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in treating m...

FDA Approves NovoCure Device for mNSCLC Treatment

Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains t...

Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune's Market Potential

H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of $30.00. Emi...

NovoCure's Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion

Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00. The company...

Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)

Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of $28.00. Jo...

NovoCure's Growth Potential Boosted by FDA Approval and Market Expansion

NovoCure: There Is Still More Upside

ARGNF

ARGX

NVCR

ZLAB

Press Releases

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

Novocure to Report Second Quarter 2024 Financial Results

CereVasc Announces Appointments of New Directors

Novocure Reports Second Quarter 2024 Financial Results

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Novocure Announces Planned CEO Transition

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Novocure to Report Third Quarter 2024 Financial Results

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

PODD

Artivion

Alphatec Holdings

AtriCure

Axogen

Axonics

CeriBell

Conmed

Enovis

Paragon 28

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

iRadimed

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

LeMaitre Vascular

Inari Medical

Envista Holdings Corporation Common Stock

Envista Holdings

Orthofix Medical

Omnicell

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

SI-BONE

Surmodics

TransMedics Gr

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

HC Wainwright & Co.

Evercore ISI Group

Wells Fargo

Piper Sandler

JP Morgan

NovoCure shares are trading higher after the company announced FDA approval of Optune Lua for the treatment of metastatic non-small cell lung cancer. Also, HC Wainwright & Co. upgraded the stock from Neutral to Buy and raised its price target from $24 to $30.

Comments

NovoCure

Actualités

Dernières nouvelles pour NovoCure (NASDAQ:NVCR) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL